Inclusion Criteria:

- male or female patients, age >/=18 years

- locally recurrent or metastatic HER2-positive breast cancer

- disease progression during or up to 12 months after prior adjuvant therapy with
trastuzumab

- LVEF >/=55% at baseline

Exclusion Criteria:

- prior treatment with bevacizumab or capecitabine

- anthracyclines in prior adjuvant or neoadjuvant treatment exceeding cumulative dose
of 360mg/m2 for doxorubicin and 720mg/kg for epirubicin

- chronic daily treatment with corticosteroids (>10mg/day methylprednisolone
equivalent; excluding inhaled corticosteroids), or aspirin (>325mg/day), or
clopidogrel (>75mg/day)

- clinically significant cardiac disease, or cardiac toxicity during previous
trastuzumab therapy

- evidence of spinal cord compression or CNS metastasis

- history of other malignancy, unless disease-free for >/=5 years or treated curatively
for carcinoma in situ of the cervix or non-melanomatous skin cancer